NEW YORK, March 11 (GenomeWeb News) - SurroMed and Biogen have extended their collaborative biomarker study, SurroMed said today.

 

SurroMed, based in Mountain View, Calif., will continue to analyze samples from multiple sclerosis patients treated with a drug from Biogen, using proteomics, metabolomics, and cytometry, to identify biomarkers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.